Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Roivant Sciences leads the 50 pharmaceutical companies ranked by P/S ratio, at 3397, ahead of Dianthus Therapeutics (2323) and Protagonist Therapeutics (180). Figures as of 19 Nov 2026, 00:22 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- First
- Roivant Sciences3397
- Median
- 6.9
- Combined market value
- HUF 1699.02T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant SciencesROIV · Health Care | 3397 | HUF 9.42T | HUF 13,007.08 | 0.05% up | 90% up | ||
| 2 | Dianthus TherapeuticsDNTH · Health Care | 2323 | HUF 1.59T | HUF 28,203.84 | 3.45% down | 113% up | ||
| 3 | Protagonist TherapeuticsPTGX · Health Care | 180 | HUF 2.79T | HUF 42,705.41 | 2.00% up | 46% up | ||
| 4 | CytokineticsCYTK · Health Care | 81.2 | HUF 2.4T | HUF 17,235.31 | 0.64% down | 20% down | ||
| 5 | Rhythm PharmaceuticalsRYTM · Health Care | 43.5 | HUF 2.77T | HUF 39,978.39 | 2.08% up | 13% up | ||
| 6 | InsmedINSM · Health Care | 43.3 | HUF 8.83T | HUF 40,233.63 | 1.69% down | 40% down | ||
| 7 | BridgeBio PharmaBBIO · Health Care | 30.3 | HUF 5.1T | HUF 26,198.88 | 1.58% up | 17% up | ||
| 8 | Ligand PharmaceuticalsLGND · Health Care | 22.3 | HUF 2.01T | HUF 100,318.77 | 1.67% up | 43% up | ||
| 9 | Ascendis PharmaASND · Health Care | 22.2 | HUF 5.96T | HUF 90,787.63 | 0.32% down | 28% up | ||
| 10 | Eli LillyLLY · Health Care | 18.9 | HUF 413.65T | HUF 464,382.76 | 2.32% down | 35% up | ||
| 11 | Royalty PharmaRPRX · Health Care | 16.6 | HUF 13.26T | HUF 23,062.13 | 0.01% down | 78% up | ||
| 12 | TG TherapeuticsTGTX · Health Care | 16.2 | HUF 3.36T | HUF 22,205.74 | 5.44% up | 107% up | ||
| 13 | Mirum PharmaceuticalsMIRM · Health Care | 11.6 | HUF 2.03T | HUF 31,061.84 | 0.59% up | 31% up | ||
| 14 | Vertex PharmaceuticalsVRTX · Health Care | 11.3 | HUF 45.68T | HUF 180,161.37 | 0.42% up | 27% up | ||
| 15 | Axsome TherapeuticsAXSM · Health Care | 11.0 | HUF 2.37T | HUF 45,002.56 | 1.43% down | 7% down | ||
| 16 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.0 | HUF 2.51T | HUF 31,921.59 | 0.06% down | 126% up | ||
| 17 | Travere TherapeuticsTVTX · Health Care | 9.8 | HUF 1.62T | HUF 16,872.60 | 1.68% down | 44% up | ||
| 18 | Corcept TherapeuticsCORT · Health Care | 9.7 | HUF 2.49T | HUF 22,766.59 | 3.25% down | 8% down | ||
| 19 | Madrigal PharmaceuticalsMDGL · Health Care | 9.6 | HUF 3.11T | HUF 133,691.19 | 5.67% down | 24% down | ||
| 20 | BeOne MedicinesONC · Health Care | 8.6 | HUF 15.48T | HUF 135,545.02 | 2.34% down | 17% up | ||
| 21 | GenmabGMAB · Health Care | 8.4 | HUF 10.55T | HUF 17,117.76 | 1.91% down | 70% up | ||
| 22 | AbbVieABBV · Health Care | 8.3 | HUF 169.79T | HUF 96,053.60 | 2.33% down | 26% up | ||
| 23 | United TherapeuticsUTHR · Health Care | 7.7 | HUF 8.26T | HUF 193,893.87 | 1.16% down | 23% up | ||
| 24 | Arrowhead PharmaceuticalsARWR · Health Care | 7.3 | HUF 2.05T | HUF 14,478.06 | 0.28% up | 10% up | ||
| 25 | Johnson & JohnsonJNJ · Health Care | 7.0 | HUF 220.47T | HUF 91,583.57 | 2.15% down | 38% up | ||
| 26 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | HUF 32.85T | HUF 317,546.80 | 1.28% down | 36% up | ||
| 27 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | HUF 6.72T | HUF 50,174.50 | 4.54% down | 66% down | ||
| 28 | NovartisNVS · Health Care | 5.4 | HUF 98.45T | HUF 52,125.73 | 2.46% down | 25% up | ||
| 29 | AlkermesALKS · Health Care | 5.3 | HUF 2.64T | HUF 15,734.10 | 3.08% up | 58% up | ||
| 30 | Merck & CoMRK · Health Care | 5.2 | HUF 114.07T | HUF 46,272.04 | 3.90% down | 51% up | ||
| 31 | Ionis PharmaceuticalsIONS · Health Care | 4.8 | HUF 1.53T | HUF 9,198.66 | 1.59% up | 64% down | ||
| 32 | AstraZenecaAZN · Health Care | 4.7 | HUF 93.11T | HUF 60,034.76 | 1.93% down | 2% up | ||
| 33 | Abbott LaboratoriesABT · Health Care | 4.1 | HUF 60.77T | HUF 35,088.56 | 0.22% down | 17% down | ||
| 34 | Novo NordiskNVO · Health Care | 3.8 | HUF 58.36T | HUF 13,242.17 | 3.12% down | 17% down | ||
| 35 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | HUF 5.34T | HUF 83,211.08 | 2.93% up | 37% up | ||
| 36 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | HUF 4T | HUF 20,630.65 | 4.99% up | 11% up | ||
| 37 | ZoetisZTS · Health Care | 3.7 | HUF 11.68T | HUF 28,737.83 | 2.50% up | 29% down | ||
| 38 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | HUF 4.19T | HUF 5,030.88 | 1.28% up | 5% up | ||
| 39 | Legend BiotechLEGN · Health Care | 3.1 | HUF 1.06T | HUF 5,457.40 | 0.87% up | 42% down | ||
| 40 | PTC TherapeuticsPTCT · Health Care | 2.9 | HUF 1.69T | HUF 20,227.64 | 0.22% down | 20% down | ||
| 41 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.9 | HUF 16.55T | HUF 14,182.52 | 0.92% down | 74% up | ||
| 42 | Elanco Animal HealthELAN · Health Care | 2.8 | HUF 4.48T | HUF 8,966.93 | 3.29% up | 20% up | ||
| 43 | PfizerPFE · Health Care | 2.6 | HUF 53.71T | HUF 9,423.67 | 1.44% down | 14% up | ||
| 44 | Bristol-Myers SquibbBMY · Health Care | 2.5 | HUF 40.89T | HUF 20,002.63 | 2.92% down | 34% up | ||
| 45 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | HUF 2.56T | HUF 7,348.18 | 3.60% up | 83% up | ||
| 46 | Takeda PharmaceuticalTAK · Health Care | 2.4 | HUF 22.82T | HUF 7,143.32 | 1.71% down | 54% up | ||
| 47 | SanofiSNY · Health Care | 2.3 | HUF 38T | HUF 15,824.78 | 0.86% down | 4% down | ||
| 48 | GSKGSK · Health Care | 2.2 | HUF 32.7T | HUF 16,315.11 | 1.34% down | 6% up | ||
| 49 | ViatrisVTRS · Health Care | 1.6 | HUF 7.81T | HUF 6,810.84 | 0.83% down | 96% up | ||
| 50 | GrifolsGRFS · Health Care | 0.7 | HUF 1.94T | HUF 2,844.56 | 1.85% down | 1% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 335.8 HUF). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/S ratio?
Roivant Sciences (3397), Dianthus Therapeutics (2323) and Protagonist Therapeutics (180) are the top three of the 50 pharmaceutical companies ranked by P/S ratio as of 19 Nov 2026, 00:22 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of HUF 1699.02T as of 19 Nov 2026, 00:22 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.